St.

Anthony’s College
Nursing Department

DRUG STUDY
Name of Patient:RBT Attending Physician: Dr.MP
Age: 42 yrs.old Ward/Bed Number: IM- 2011 BED 2 Impression/ Diagnosis: PERIPHERAL NEUROPATHY

Name of Drug Dosage, Mech. of Indication Adverse Reactions Special Precautions Nursing Responsibilities
Route, Action
Freq.,
Timing
Generic: Dosage: •Selectively Short-term •Hypersensitivity Reactions: Gastrointestinal effects  Assess client for history of allergic
Etoricoxib 120 mg/tab inhibits cyclo- treatment of Swelling of the face, lips, Upper gastrointestinal reaction to Arcoxia or for previous
1 tablet oxygenase- 2 moderate pain tongue or throat which may complications [perforations, heart failure, heart attack, bypass
(COX-2) COX- cause difficulty in swallowing ulcers or bleedings (PUBs)], surgery, angina, peripheral arterial
Route: 2 which is an For the or breathing some of them resulting in fatal disease, or transient ischaemic
Oral isoform of the symptomatic relief •Insomnia or increased outcome, have occurred in attack.
Brand: enzyme that of osteoarthritis anxiety patients treated with etoricoxib.
Arcoxia has been (OA), rheumatoid •Severe increase in blood  Monitor blood pressure regularly
postulated to arthritis (RA), pressure Cardiovascular effects while taking this medication.
be primarily ankylosing • Confusion, Clinical trials suggest that the
Frequency: responsible for spondylitis, and the Hallucinations selective COX-2 inhibitor class  Take medication with a glass of
OD the synthesis pain and signs of •Decreased Platelets of drugs may be associated water to avoid dehydration.
of mediators of inflammation •Atrial Fibrillation or abnormal with a risk of thrombotic events
pain, associated with rhythm of the heart (especially myocardial  Arcoxia may be taken regardless of
inflammation, acute gouty •Heart failure infarction (MI) and stroke), food intake.
Timing: and fever. arthritis. •Stomach pain or Stomach relative to placebo and some
As needed ulcers that may become NSAIDs. As the cardiovascular  Stop the medication immediately if
for pain •Affects central serious and may bleed, and risks of etoricoxib may gastrointestinal lesions occur.
nervous may occur at any time during increase with dose and
system use and without warning duration of exposure, the
functions shortest duration possible and
Classification: towards fever Contraindications Side Effects: the lowest effective daily dose
induction, pain : should be used. The patient's
Functional: perception and  Active peptic  feeling sick (nausea), need for symptomatic relief
NSAIDS cognitive ulceration or vomiting. and response to therapy
function. active gastro-  heartburn, indigestion, should be re-evaluated
intestinal (GI) uncomfortable feeling or periodically, especially in
•Does not patients with osteoarthritis
inhibit COX-1 bleeding. pain in the stomach. Renal effects
at thereby has  Patients who  diarrhoea. Renal prostaglandins may play
no effect on have a compensatory role in the
 swelling of the legs,
gastric experienced maintenance of renal
ankles or feet.
prostaglandin bronchospasm, perfusion. Therefore, under
synthesis and acute rhinitis,  high blood pressure. conditions of compromised
on platelet nasal polyps,  dizziness. renal perfusion, administration
function angioneurotic  headache. of etoricoxib may cause a
oedema, reduction in prostaglandin
urticaria, or formation and, secondarily, in
allergic-type renal blood flow, and thereby
reactions after impair renal function. Patients
taking at greatest risk of this
acetylsalicylic response are those with pre-
acid or NSAIDs existing significantly impaired
including COX- renal function, uncompensated
2 inhibitors. heart failure, or cirrhosis.
 Severe hepatic Monitoring of renal function in
dysfunction such patients should be
(serum albumin considered.
<25 g/l or Child-
Pugh score Hepatic effects
≥10). Elevations of alanine
 Estimated renal aminotransferase (ALT) and/or
creatinine aspartate aminotransferase
clearance <30 (AST) (approximately three or
ml/min. more times the upper limit of
 Inflammatory normal) have been reported in
bowel disease. approximately 1% of patients
 Patients with in clinical trials treated for up to
hypertension one year with etoricoxib 30, 60
whose blood and 90 mg daily.
pressure is
persistently
elevated above
140/90mmHg
and has not
been
 adequately
controlled.
 Established
ischaemic heart
disease,
peripheral
arterial disease,
and/or
cerebrovascular
disease